{"url_path":"/sec/anvs/8-k/2026-05-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-064514-index.html","accession_number":"0001104659-26-064514","cik":"0001477845","ticker":"ANVS","issuer_name":"Annovis Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-064514-index.html","primary_entity_key":"0001477845","primary_entity_name":"Annovis Bio, Inc."},"word_count":113,"has_tables":true,"body_markdown":"**Item 9.01**\n**Financial Statements and Exhibits**\n\n \n\n**Exhibit Number**\n \n**Description**\n\n \n \n \n\n[4.1](tm2615162d1_ex4-1.htm)\n \n[Form of Warrant](tm2615162d1_ex4-1.htm)\n\n \n \n \n\n[5.1](tm2615162d1_ex5-1.htm)\n \n[Opinion of Loeb & Loeb LLP](tm2615162d1_ex5-1.htm)\n\n \n \n \n\n[10.1](tm2615162d1_ex10-1.htm)\n \n[Underwriting Agreement](tm2615162d1_ex10-1.htm)\n\n \n \n \n\n[23.1](tm2615162d1_ex5-1.htm)\n \n[Consent of Loeb & Loeb LLP (contained in Exhibit 5.1)](tm2615162d1_ex5-1.htm)\n\n \n \n \n\n[99.1](tm2615162d1_ex99-1.htm)\n \n[Press Release, dated May 19, 2026](tm2615162d1_ex99-1.htm)\n\n \n \n \n\n[99.2](tm2615162d1_ex99-2.htm)\n \n[Press Release, dated May 20, 2026](tm2615162d1_ex99-2.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n3\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**ANNOVIS BIO, INC.**\n\n \n \n\nDate: May 20, 2026\nBy:\n/s/ Maria Maccecchini\n\n \n \nName:\nMaria Maccecchini\n\n \n \nTitle:\nPresident and Chief Executive Officer\n\n \n\n4"}